The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

Cell, Journal Year: 2021, Volume and Issue: 185(3), P. 447 - 456.e11

Published: Dec. 24, 2021

Language: Английский

---

Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa

Science, Journal Year: 2022, Volume and Issue: 376(6593)

Published: March 15, 2022

We provide two methods for monitoring reinfection trends in routine surveillance data to identify signatures of changes risk and apply these approaches from South Africa's severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic date. Although we found no evidence increased associated with circulation the Beta (B.1.351) or Delta (B.1.617.2) variants, did find clear, population-level suggest immune evasion by Omicron (B.1.1.529) variant previously infected individuals Africa. Reinfections occurring between 1 November 2021 31 January 2022 were detected all three previous waves, there has been an increase having a third infection since mid-November 2021.

Language: Английский

---

Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current COVID‐19 vaccines

Journal of Medical Virology, Journal Year: 2022, Volume and Issue: 94(5), P. 1825 - 1832

Published: Jan. 13, 2022

Currently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide as an Omicron variant. This variant is a heavily mutated virus and designated of concern by the World Health Organization (WHO). WHO cautioned that SARS-CoV-2 held very high risk infection, reigniting anxieties about economy's recovery from 2-year pandemic. The extensively likely to internationally, posing infection surges with serious repercussions in some areas. According preliminary data, higher reinfection. On other hand, whether current COVID-19 vaccines could effectively resist new strain still under investigation. However, there limited information on situation variant, such genomics, transmissibility, efficacy vaccines, treatment, management. review focused transmission, effectiveness against which will be helpful for further investigation SARS-CoV-2.

Language: Английский

---

The evolution of SARS-CoV-2

Nature Reviews Microbiology, Journal Year: 2023, Volume and Issue: 21(6), P. 361 - 379

Published: April 5, 2023

Language: Английский

---

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study

The Lancet, Journal Year: 2022, Volume and Issue: 399(10323), P. 437 - 446

Published: Jan. 1, 2022

Language: Английский

---

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

New England Journal of Medicine, Journal Year: 2022, Volume and Issue: 387(14), P. 1279 - 1291

Published: Sept. 16, 2022

The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine are not known.In this ongoing, phase 2-3 study, we compared 50-μg (25 μg each ancestral Wuhan-Hu-1 omicron B.1.1.529 [BA.1] spike messenger RNAs) with previously authorized mRNA-1273 booster. We administered or as a second in adults who had received two-dose (100-μg) primary series first (50-μg) dose (≥3 months earlier). objectives were to assess safety, reactogenicity, at 28 days after dose.Interim results presented. Sequential groups participants 50 (437 participants) (377 dose. median time between boosters was similar for (136 days) (134 days). In no previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, geometric mean titers neutralizing antibodies against BA.1 variant 2372.4 (95% confidence interval [CI], 2070.6 2718.2) receipt 1473.5 CI, 1270.8 1708.4) addition, elicited 727.4 632.8 836.1) 492.1 431.1 561.9), respectively, BA.4 BA.5 (BA.4/5), also higher binding antibody responses multiple other variants (alpha, beta, gamma, delta) than Safety reactogenicity two vaccines. Vaccine effectiveness assessed study; an exploratory analysis, SARS-CoV-2 infection occurred 11 9 booster.The that superior those mRNA-1273, without evident concerns. (Funded by Moderna; ClinicalTrials.gov number, NCT04927065.).

Language: Английский

---

SARS-CoV-2 Omicron variant: recent progress and future perspectives

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: April 28, 2022

Abstract Since the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there have been a few variants severe acute respiratory syndrome 2 (SARS-CoV-2), one which is Omicron variant (B.1.1.529). The most mutated SARS-CoV-2 variant, and its high transmissibility immune evasion ability raised global concerns. Owing to enhanced transmissibility, has rapidly replaced Delta as dominant in several regions. However, recent studies shown that exhibits reduced pathogenicity due altered cell tropism. In addition, significant resistance neutralizing activity vaccines, convalescent serum, antibody therapies. present review, advances molecular clinical characteristics infectivity, pathogenicity, was summarized, potential therapeutic applications response infection were discussed. Furthermore, we highlighted future waves strategies end pandemic.

Language: Английский

---

Acute and postacute sequelae associated with SARS-CoV-2 reinfection

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(11), P. 2398 - 2405

Published: Nov. 1, 2022

Abstract First infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated increased risk of and postacute death sequelae in various organ systems. Whether reinfection adds to risks incurred after first unclear. Here we used the US Department Veterans Affairs’ national healthcare database build a cohort individuals one SARS-CoV-2 ( n = 443,588), (two or more infections, 40,947) noninfected control 5,334,729). We inverse probability-weighted survival models estimate 6-month burdens death, hospitalization incident sequelae. Compared no reinfection, contributed additional (hazard ratio (HR) 2.17, 95% confidence intervals (CI) 1.93–2.45), (HR 3.32, CI 3.13–3.51) including pulmonary, cardiovascular, hematological, diabetes, gastrointestinal, kidney, mental health, musculoskeletal neurological disorders. The were evident regardless vaccination status. most pronounced phase but persisted at 6 months. controls, cumulative repeat according number infections. Limitations included mostly white males. evidence shows that further increases multiple systems phase. Reducing overall burden disease due will require strategies for prevention.

Language: Английский

---

The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant

Journal of Medical Virology, Journal Year: 2022, Volume and Issue: 94(6), P. 2376 - 2383

Published: Feb. 4, 2022

Recently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) was first identified in Botswana November 2021. It reported to World Health Organization (WHO) on 24. On 26, 2021, according advice of scientists who are part WHO's Technical Advisory Group SARS-CoV-2 Virus Evolution (TAG-VE), WHO defined strain as a concern (VOC) and named it Omicron. Compared other four VOCs (Alpha, Beta, Gamma, Delta), most highly mutated strain, with 50 mutations accumulated throughout genome. The contains at least 32 spike protein, which twice many Delta variant. Studies have shown that carrying can increase infectivity immune escape compared early wild-type VOCs. is becoming dominant countries worldwide brings new challenges preventing controlling disease 2019 (COVID-19). current review article aims analyze summarize information data about biological characteristics amino acid mutations, epidemic characteristics, escape, vaccine reactivity variant, hoping provide scientific reference for monitoring, prevention, development strategies

Language: Английский

---

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

New England Journal of Medicine, Journal Year: 2021, Volume and Issue: 386(5), P. 494 - 496

Published: Dec. 29, 2021

Language: Английский

---